Crohn's Disease Clinical Trials

32 studies are recruiting for crohn's disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

   Crohn's disease (CD) and Ulcerative colitis (UC) are 2 types of inflammatory bowel diseases which cause long-lasting, severe inflammation (redness, swelling) in the digestive tract. CD can affect any part of the digestive tract causing many different symptoms including belly pain, diarrhea, tiredne…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Digestive Health Specialists /ID# 280827, Dothan, Alabama

   Locations

   36 in total

   Run by

   AbbVie

   See if you can join NCT07697456 on ClinicalTrials.gov

2. A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

   The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinica…

   Stage

   Phase 3

   Ages

   16 to 80

   Site

   GI Alliance - Sun City ( Site 5118), Sun City, Arizona

   Locations

   499 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06430801 on ClinicalTrials.gov

3. A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

   Ulcerative Colitis (UC) and Crohn's Disease (CD) are long-term conditions in the gut that can cause diarrhea, swelling (inflammation), bleeding from the anus, and belly pain. The main aim of this study is to check for how many participants with UC and CD signs and symptoms disappear after 3.5 month…

   Stage

   Phase 4

   Ages

   18 to 80

   Site

   Gastro Health, Birmingham, Alabama

   Locations

   101 in total

   Run by

   Takeda

   See if you can join NCT06581328 on ClinicalTrials.gov

4. A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

   Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active C…

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Phoenix Children's Hospital /ID# 255766, Phoenix, Arizona

   Locations

   85 in total

   Run by

   AbbVie

   See if you can join NCT05995353 on ClinicalTrials.gov

5. A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

   The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual …

   Stage

   Phase 4

   Ages

   18 to 70

   Site

   Digestive Health Specialsits, Dothan, Alabama

   Locations

   48 in total

   Run by

   Takeda

   See if you can join NCT06045754 on ClinicalTrials.gov

6. A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

   This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 3 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).

   Stage

   Phase 2

   Ages

   18 to 85

   Site

   Gastro Care Institute, Lancaster, California

   Locations

   225 in total

   Run by

   Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)

   See if you can join NCT06226883 on ClinicalTrials.gov

7. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

   The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 6…

   Stage

   Phase 3

   Ages

   18 to 70

   Site

   Digestive Health Specialists, Dothan, Alabama

   Locations

   183 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06937099 on ClinicalTrials.gov

8. A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.

   Stage

   Phase 3

   Ages

   2 to 17

   Site

   Cedars Sinai Medical Center, Los Angeles, California

   Locations

   85 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT05923073 on ClinicalTrials.gov

9. An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab

   Background: Crohn s disease (CD) is an inflammatory bowel disease. It causes inflammation of the gut. Symptoms may include diarrhea, abdominal pain, fatigue, weight loss and malnutrition. CD has no cure, but symptoms can sometimes be controlled with medicine. Researchers want to see if it is safe t…

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT03167437 on ClinicalTrials.gov

10. A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

    Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study i…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    United Medical Doctors, Murrieta, California

    Locations

    190 in total

    Run by

    Takeda

    See if you can join NCT06233461 on ClinicalTrials.gov

11. A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

    The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Contin…

    Stage

    Phase 3

    Ages

    2 to 19

    Site

    UCSF Medical Center at Mission Bay, San Francisco, California

    Locations

    68 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT04844606 on ClinicalTrials.gov

12. A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

    Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn…

    Stage

    Phase 3

    Ages

    2 to 17

    Site

    Connecticut Children's Medical Center, Hartford, Connecticut

    Locations

    81 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT05509777 on ClinicalTrials.gov

13. Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease

    The goal of this clinical trial is to learn about the effects of fluconazole in patients who plan to start or are currently undergoing standard of care treatment and plan to dose-escalate an IL-23 therapy for their Crohn's disease. The main question it aims to assess is whether or not patient respo…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Weill Cornell Medicine, New York, New York

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT06274554 on ClinicalTrials.gov

14. Behavioral Therapy for Crohn's Disease

    People living with Crohn's disease (CD) experience psychological and emotional symptoms, in addition to known chronic and disabling physical symptoms, which prevent them from living their life to the fullest (flourishing). Depression and anxiety are experienced by 30% of people living with CD and 6…

    Stage

    Not phased

    Ages

    18 to 65

    Site

    Icahn School of Medicine at Mount Sinai, New York, New York

    Locations

    2 in total

    Run by

    Icahn School of Medicine at Mount Sinai

    See if you can join NCT06512597 on ClinicalTrials.gov

15. A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

    The main aim of this study is to learn how the body of a child or teenager with moderately to severely active ulcerative colitis (UC) or Crohn's disease (CD) processes vedolizumab (pharmacokinetics) given just under the skin subcutaneously (SC). The participants will be treated with vedolizumab for…

    Stage

    Phase 3

    Ages

    2 to 17

    Site

    Children's Hospital Of Orange County, Orange, California

    Locations

    54 in total

    Run by

    Takeda

    See if you can join NCT06100289 on ClinicalTrials.gov

16. An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

    This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active CD. Study details include: The study duration may be up to 35 …

    Stage

    Phase 3

    Ages

    16 to 80

    Site

    Onyx Clinical Research - Site Number: 8400021, Peoria, Arizona

    Locations

    301 in total

    Run by

    Sanofi

    See if you can join NCT07184931 on ClinicalTrials.gov

17. Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

    Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Digestive Health Specialists /ID# 266216, Dothan, Alabama

    Locations

    255 in total

    Run by

    AbbVie

    See if you can join NCT06548542 on ClinicalTrials.gov

18. Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

    Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess how safe and effec…

    Stage

    Phase 3

    Ages

    2 to 17

    Site

    UCSF Benioff Children's Hospital - Oakland /ID# 262217, Oakland, California

    Locations

    85 in total

    Run by

    AbbVie

    See if you can join NCT06332534 on ClinicalTrials.gov

19. A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

    The main aim of this study is to learn about medical problems (adverse events) if vedolizumab subcutaneously (SC) is given to a child or teenager with UC or CD for a long time. Other aims are to understand if the long time use of vedolizumab SC has an impact on the time period until hospital visits…

    Stage

    Phase 3

    Ages

    2 to 17

    Site

    The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

    Locations

    54 in total

    Run by

    Takeda

    See if you can join NCT06405087 on ClinicalTrials.gov

20. A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

    This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD). Study details include: The study duration may be up to 286 weeks including: * 40-…

    Stage

    Phase 3

    Ages

    16 to 80

    Site

    Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039, Colorado Springs, Colorado

    Locations

    35 in total

    Run by

    Sanofi

    See if you can join NCT07184944 on ClinicalTrials.gov

21. A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

    The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Diseas…

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Peak Gastroenterology Associates, Colorado Springs, Colorado

    Locations

    138 in total

    Run by

    Takeda

    See if you can join NCT06227910 on ClinicalTrials.gov

22. A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)

    Crohn's Disease and Ulcerative Colitis are two types of inflammatory bowel disease (IBD), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel. TAK-279 is a medicine which helps to block inflammation. This study is an extension …

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Woodholme Gastroenterology Associates, Glen Burnie, Maryland

    Locations

    16 in total

    Run by

    Takeda

    See if you can join NCT06764615 on ClinicalTrials.gov

23. Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis

    This study proposes a randomized prospective study comparing the Kono-S anastomosis to the standard side-to-side anastomosis.This will be a multi-center randomized prospective trial. Patients with Crohn's ileitis or Crohn's ileocolitis requiring resection will be randomized to undergo either the Ko…

    Stage

    Not phased

    Ages

    18 to 90

    Site

    Weill Cornell Medical College, New York, New York

    Locations

    15 in total

    Run by

    Weill Medical College of Cornell University

    See if you can join NCT03256240 on ClinicalTrials.gov

24. A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

    The study is an extension of two parent studies (MLN0002-3024 [NCT04779307] and MLN0002-3025 [NCT04779320]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.

    Stage

    Phase 3

    Ages

    2 and older

    Site

    Phoenix Childrens Hospital - Thomas Rd - PIN, Phoenix, Arizona

    Locations

    98 in total

    Run by

    Takeda

    See if you can join NCT05442567 on ClinicalTrials.gov

25. A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease

    This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up…

    Stage

    Phase 2

    Ages

    18 to 75

    Site

    Investigational Site Number: 8400024, Tucson, Arizona

    Locations

    66 in total

    Run by

    Sanofi

    See if you can join NCT06958536 on ClinicalTrials.gov